A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma

Inclusion Criteria: * Provide written informed consent/assent for the trial. * Be ≥18 and ≤ 75 years of age on day of signing informed consent, no matter male or female. * IMDC favourable risk（IMDC score 0）. * ECOG PS 0-1. * Have estimated life expectancy of at least 3 months. * Have histologically or cytologically confirmed diagnosis of RCC with mainly clear cell carcinoma component. * Have received no prior systemic therapy for advanced RCC，Including but not limited to Immunotherapy, target therapy, chemotherapy, biological therapy, etc. Note: Prior neoadjuvant/adjuvant therapies are acceptable if disease progression occurred \> 6 months after last dosage of neoadjuvant/adjuvant treatment. * Have measurable disease per RECIST v1.1 . * Adequate organ function. * Contraception from entering the trial，until 120 days after the last administration of the investigational drug. * Willing to comply with the scheduled visits, treatment plans, and other requirements of the trial. Exclusion Criteria: * non-clear cell renal cell carcinoma，nccRCC（e.g. chromophobe, papillary) * Has active autoimmune disease that might deteriorate when receiving an immunostimulatory agents. Subjects with diabetes type I, vitiligo, psoriasis, hypo-or hyperthyroid disease not requiring immunosuppressive treatment are eligible. * Has a known additional malignancy that has progressed or has required active treatment in the last 5 years. Note: Subjects with basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or carcinoma in situ are not excluded. * Eligible for surgery. * History of severe bleeding or coagulation disorders. * History of abdominal fistula or gastrointestinal perforation related to anti VEGF therapy. * Has previously received systemic therapy. * Has newly diagnosed brain metastases or known symptomatic brain metastases requiring steroids. * Had major surgery 4 weeks prior to receiving first dose of trial treatment. * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to receiving first dose of trial treatment. * Has an active tuberculosis and syphilitic infection. * Has a known history of Human Immunodeficiency Virus (HIV) infection (HIV antibodies). * Has known active Hepatitis B (e.g., Hepatitis B surface antigen \[HBsAg\] reactive and HBV-DNA\>2000 IU/ml) or Hepatitis C virus (e.g., HCV RNA \[qualitative\] is detected). * Has been pregnant or breastfeeding. * Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.